Lipothiophosphoramidates for gene delivery: critical role of the cationic polar headgroup

被引:19
作者
Fraix, Aurore [1 ]
Montier, Tristan [2 ,3 ]
Le Gall, Tony [2 ]
Sevrain, Charlotte M. [1 ]
Carmoy, Nathalie [2 ,3 ]
Lindberg, Mattias F. [2 ]
Lehn, Pierre [2 ,3 ]
Jaffres, Paul-Alain [1 ,2 ]
机构
[1] Univ Europeenne Bretagne, Univ Brest, CEMCA, IFR ScInBIoS 148,CNRS UMR 6521, F-29238 Brest, France
[2] Univ Bretagne Occidentale, IBiSA SynNanoVect Platform, IFR ScInBIoS 148, Fac Med Morvan,CS 51819, F-29218 Brest 2, France
[3] Univ Bretagne Occidentale, IFR ScInBIoS 148, INSERM U613, Fac Med Morvan,CS 51819, F-29218 Brest 2, France
关键词
TRANSFECTION EFFICIENCY; CELLULAR TOXICITY; LIPIDS; COMPLEXES; VECTORS; PHOSPHONOLIPIDS; INTERFERENCE; DERIVATIVES; IMIDAZOLE; CARRIERS;
D O I
10.1039/c2ob06812e
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
When considering a family of cationic lipids designed for gene delivery, the nature of the cationic polar head probably has a great influence on both the transfection efficacy and toxicity. Starting from a cationic lipothiophosphoramidate bearing a trimethylammonium headgroup, we report herein the impact on gene transfection activity of the replacement of the trimethylammonium moiety by a trimethylphosphonium or a trimethylarsonium group. A series of three different human epithelial cell lines were used for the experimental transfection studies (HeLa, A549 and 16HBE14o(-)). The results basically showed that such structural modifications of the cationic headgroup can lead to a high transfection efficacy at low lipid/DNA charge ratios together with a low cytotoxicity. It thus appears that the use of a trimethylarsonium cationic headgroup for the design of efficient gene carriers, which was initially proposed in the lipophosphoramidate series, can be extended to other series of cationic lipids and might therefore have great potential for the development of novel non-viral vectors in general.
引用
收藏
页码:2051 / 2058
页数:8
相关论文
共 41 条
[1]   Lipophosphonate/lipophosphoramidates: A family of synthetic vectors efficient for gene delivery [J].
Berchel, Mathieu ;
Le Gall, Tony ;
Couthon-Gourves, Helene ;
Haelters, Jean-Pierre ;
Montier, Tristan ;
Midoux, Patrick ;
Lehn, Pierre ;
Jaffres, Paul-Alain .
BIOCHIMIE, 2012, 94 (01) :33-41
[2]   Vaccine delivery methods using viral vectors [J].
Brave, Andreas ;
Ljungberg, Karl ;
Wahren, Britta ;
Liu, Margaret A. .
MOLECULAR PHARMACEUTICS, 2007, 4 (01) :18-32
[3]   Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference [J].
Desigaux, Lea ;
Sainlos, Matthieu ;
Lambert, Olivier ;
Chevre, Raphael ;
Letrou-Bonneval, Emilie ;
Vigneron, Jean-Pierre ;
Lehn, Pierre ;
Lehn, Jean-Marie ;
Pitard, Bruno .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (42) :16534-16539
[4]   Systemic administration of cationic phosphonolipids/DNA complexes and the relationship between formulation and lung transfection efficiency [J].
Floch, V ;
Delépine, P ;
Guillaume, C ;
Loisel, S ;
Chassé, S ;
Le Bolc'h, G ;
Gobin, E ;
Leroy, JP ;
Férec, C .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2000, 1464 (01) :95-103
[5]   Cation substitution in cationic phosphonolipids:: A new concept to improve transfection activity and decrease cellular toxicity [J].
Floch, V ;
Loisel, S ;
Guenin, E ;
Hervé, AC ;
Clément, JC ;
Yaouanc, JJ ;
des Abbayes, H ;
Férec, C .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (24) :4617-4628
[6]   Cationic lipo-thiophosphoramidates for gene delivery: synthesis, physico-chemical characterization and gene transfection activity - comparison with lipo-phosphoramidates [J].
Fraix, Aurore ;
Montier, Tristan ;
Carmoy, Nathalie ;
Loizeau, Damien ;
Burel-Deschamps, Laure ;
Le Gall, Tony ;
Giamarchi, Philippe ;
Couthon-Gourves, Helene ;
Haelters, Jean-Pierre ;
Lehn, Pierre ;
Jaffres, Paul-Alain .
ORGANIC & BIOMOLECULAR CHEMISTRY, 2011, 9 (07) :2422-2432
[7]   Gene therapy for cancer (Reprinted from Eur J Cancer, vol 35, pg 867-885, 1999) [J].
Gómez-Navarro, J ;
Curiel, DT ;
Douglas, JT .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (14) :2039-2057
[8]   Gene therapy progress and prospects: cystic fibrosis [J].
Griesenbach, U. ;
Geddes, D. M. ;
Alton, E. W. F. W. .
GENE THERAPY, 2006, 13 (14) :1061-1067
[9]  
Guénin E, 2000, ANGEW CHEM INT EDIT, V39, P629
[10]   Cationic phosphonolipids as nonviral gene transfer agents in the lungs of mice [J].
Guillaume-Gable, C ;
Floch, V ;
Mercier, B ;
Audrézet, MP ;
Gobin, E ;
Le Bolc'h, G ;
Yaouanc, JJ ;
Clément, JC ;
Des Abbayes, H ;
Leroy, JP ;
Morin, V ;
Férec, C .
HUMAN GENE THERAPY, 1998, 9 (16) :2309-2319